Constellation Brands Inc. Common Stock vs Tango Therapeutics Inc. — how do they compare? Constellation Brands Inc. Common Stock trades at $127.6 (market cap $21.50B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Constellation Brands Inc. Common Stock is far larger — about 5.7× Tango Therapeutics Inc.'s market cap, and Constellation Brands Inc. Common Stock pays a 3.24% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals.
| STZ | TNGX | |
|---|---|---|
Market Cap | $21.50B | $3.75B |
Volume | 2,104,680 | 9,619,106 |
Sector | Consumer Staples | Health |
52-Week High | $166.68 | $32.90 |
52-Week Low | $112.77 | $7.50 |
Enterprise Value | $31.72B | $2.77B |
Dividend Yield | 3.24% | — |
Typical Hold Time | — | 0 Days |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Constellation Brands, Inc. is a US producer and marketer of beer, wine, and spirits, known for importing Mexican beer brands Corona and Modelo alongside a portfolio of wine and craft spirits labels.
Read more on STZ →Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →